Neurotrophic tropomyosin receptor kinase (NTRK) gene fusions are rare oncogenic drivers
in solid tumours. This study aimed to interrogate a large real-world database of …

The paradigm of cancer-targeted therapies has focused largely on inhibition of critical
pathways in cancer. Conversely, conditional activation of signaling pathways as a new …

Background High tumor mutation burden (TMB) can benefit immunotherapy for multiple
tumor types, but the prevalence of hypermutated breast cancer is not well described. The …

Unlike most tumor suppressor genes, the most common genetic alterations in tumor protein
p53 (TP53) are missense mutations,. Mutant p53 protein is often abundantly expressed in …

The discovery of oncogenic driver mutations rendering non-small cell lung cancer (NSCLC)
targetable by small-molecule inhibitors, and the development of immunotherapies, have …

Oncogenes that occur in≤ 5% of non-small-cell lung cancers have been defined as 'rare';
nonetheless, this frequency can correspond to a substantial number of patients diagnosed …

The combination of next-generation sequencing and advanced computational data analysis
approaches has revolutionized our understanding of the genomic underpinnings of cancer …

Purpose: To define the genetic landscape of advanced differentiated and anaplastic thyroid
cancer (ATC) and identify genetic alterations of potential diagnostic, prognostic, and …

Abstract The RAS–RAF–MEK–ERK signaling cascade is among the most frequently mutated
pathways in human cancer. Approximately 50% of melanoma patients possess a druggable …

Summary We analyzed 2,532 lung adenocarcinomas (LUAD) to identify the
clinicopathological and genomic features associated with metastasis, metastatic burden …